CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Healthcare resource utilization and costs in patients with multiple myeloma who received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were exposed to and discontinued lenalidomide in the United States.
Healthcare resource utilization and costs in patients with multiple myeloma who received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were exposed to and discontinued lenalidomide in the United States.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
既往接受过 1 至 3 线治疗的 MM 患者承受着较高的经济负担，主要归因于 MM 相关治疗，这凸显了对更具成本效益疗法的需求。
难治性多发性骨髓瘤（MM）患者常经历包含多种药物类别的多线治疗（LOTs），这可能造成严重的经济负担。在这项美国回顾性索赔数据库研究中，我们考察了接受过1至3线既往治疗的MM患者的医疗资源利用（HCRU）和费用。
来自IBM Truven MarketScan索赔数据库（2011年1月1日至2023年4月22日）的成人MM患者，需在初次MM诊断日期前连续参加医疗福利/药房计划≥12个月，并在诊断日期后接受1至3线LOTs（包括接受≥1种蛋白酶体抑制剂和免疫调节药物，以及接受并停用来那度胺）。索引日期（满足纳入标准后开始后续治疗的日期）发生在2018年1月1日之后，以获取当代成本估算。主要结局包括索引日期后的全因和MM相关医疗费用及HCRU。
主要分析纳入338例未接受索引后干细胞移植（SCT）的MM患者，平均年龄61.1岁（55.3%为男性）。在平均11.5个月的随访期间，全因医疗总费用平均为每患者每月41,614美元。MM相关医疗费用（39,699美元）占全因总费用的95%。大多数MM相关月度费用归因于药物/输注费用（71%；28,144美元）。纳入索引后SCT患者（N = 520）的敏感性分析得出了相似结果。
Patients with refractory multiple myeloma (MM) often progress through lines of therapy (LOTs) comprising multiple drug classes, which may impose severe economic burden. In this retrospective US claims database study, we examined healthcare resource utilization (HCRU) and costs of patients with MM who received 1 to 3 prior LOTs.
Adults with MM from the IBM Truven MarketScan Claims Database (1 January 2011-22 April 2023) were required to be continuously enrolled in a medical benefit/pharmacy plan for ≥12 months before initial MM diagnosis date and to have received 1 to 3 LOTs (including receiving ≥1 proteasome inhibitor and immunomodulatory drug and receiving and discontinuing lenalidomide) after diagnosis date. Index dates (start of subsequent treatment after fulfilling inclusion criteria) occurred after 1 January 2018, to capture contemporary cost estimates. Primary outcomes included all-cause and MM-related healthcare costs and HCRU after index date.
The primary analysis included 338 patients with MM without post-index stem cell transplant (SCT), with a mean age of 61.1 years (55.3% male). During an average follow-up of 11.5 months, total all-cause healthcare costs averaged US $41,614 per patient per month. MM-related healthcare costs ($39,699) contributed 95% to total all-cause costs. Most MM-related monthly costs were attributed to drug/infusion costs (71%; $28,144). Sensitivity analyses that included patients with post-index SCT ( N = 520) yielded similar results.
Patients with MM with 1 to 3 prior LOTs experienced high economic burden largely attributable to MM-related treatment, highlighting the need for more cost-effective therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
